Загрузка компании
Just reported
Q3 2026 results
From DBV Technologies's results release of 28 октября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
1,6M $
-43 % y/y
+129 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,14 $
Guided
—
No guide given
Operating income, GAAP
Actual
-64,8M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes DBV Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.48B $A+
EXELExelixis, Inc.17,3B $A+
JAZZJazz Pharmaceuticals plc15,9B $A
HALOHalozyme Therapeutics, Inc.11,6B $A+
TECHBIO-Techne Corp11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
BIIBBiogen Inc.28 окт. 2026 г.BAGraded B, now A
Полная финансовая отчётность →
Построено по собственной отчётности DBV Technologies S.A., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
